XML 27 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Balance Sheets (USD $)
Mar. 31, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 20,086,799 $ 5,646,021
Short-term investments 7,978,345 8,034,001
Accounts receivable 1,029,158 830,433
Accounts receivable from affiliated entity 43,537 36,234
Prepaid expenses and other current assets 283,044 471,328
Prepaid expenses and other current assets from affiliated entity 832,494 887,167
Deferred tax asset 62,728 62,728
Total current assets 30,316,105 15,967,912
Restricted cash 100,497 100,410
Fixed assets, net 362,889 363,021
Investment in affiliated entity 9,867,248 10,703,332
Intangible assets, net 7,041,388 7,489,315
Goodwill 10,113,371 [1] 10,113,371 [1]
Common stock warrants 266,400 267,200
Other assets 133,543 134,193
Total assets 58,201,441 45,138,754
Current liabilities:    
Accounts payable and accrued expenses 2,567,631 3,181,574
Accounts payable and accrued expenses due to affiliated entity 377,732 187,275
Accrued clinical trial expenses 2,199,880 1,405,896
Common stock warrants 10,254,959 2,859,899
Deferred revenue 201,964 353,391
Deferred revenue from affiliated entity 376,042 388,542
Total current liabilities 15,978,208 8,376,577
Deferred revenue, net of current portion 86,948 88,609
Deferred revenue from affiliated entity, net of current portion 1,492,944 1,586,694
Deferred rent 58,349 65,076
Deferred tax liabilities 164,393 164,393
Total liabilities 17,780,842 10,281,349
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 179,941 144,313
Additional paid-in capital 278,289,806 263,897,116
Accumulated deficit (238,604,249) (229,760,129)
Accumulated other comprehensive income 66,518 73,362
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 39,932,016 34,354,662
Non-controlling interest 488,583 502,743
Total stockholders' equity 40,420,599 34,857,405
Total liabilities and stockholders’ equity $ 58,201,441 $ 45,138,754
[1] Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.